Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc(TMO)股票分析

$690.000

-6.417 (-0.93%)收盘时

Loading chart…
最高
699.200
开盘
692.260
成交量加权均价
690.94
成交量
2.11M
市值
210.24B
最低
683.630
成交额
1.46B
企业价值/息税折旧摊销前利润(TTM)
23.91

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.

AI 分析 of Thermo Fisher Scientific Inc (TMO)

买入

Thermo Fisher Scientific Inc is a good buy right now, with a current price of $690 and a forward P/E ratio of 24.15, indicating reasonable valuation compared to its growth prospects. The stock has shown a 5-day change of +4.86% and a year-to-date change of +16.45%, reflecting strong momentum. However, the RSI is at 68.22, suggesting it is nearing overbought territory, which is a risk to consider.

分析师评级(15)

-4.51% 下跌空间
买入
14 买入
1 持有
0 卖出
当前: 690.00
最低
580.00
平均
658.89
最高
750.00

Morgan Stanley

2026-10-12

目标价

$730

增持

BofA

2026-10-09

目标价

$745

买入

Barclays

2026-10-07

目标价

$750

增持

Deutsche Bank

2026-09-25

目标价

$720

买入

UBS

2026-09-09

目标价

$730

买入

估值指标

Thermo Fisher Scientific Inc(TMO)当前预期市盈率为 24.15,5 年平均预期市盈率为 23.81。

预期市盈率

合理
5 年均值 P/E
23.81
当前P/E
24.15
高估
26.62
低估
20.99

预期 EV/EBITDA

高估
5 年均值 EV/EBITDA
20.76
当前EV/EBITDA
23.91
高估
22.69
低估
18.82

预期市销率

合理
5 年均值 P/S
4.71
当前P/S
5.11
高估
5.36
低估
4.06

Alphio AI 对 TMO 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%TMO

$539.08

情景价格

基

基准

基准 · 50%TMO

$476.92

情景价格

悲

悲观

悲观 · 25%TMO

$435.11

情景价格

持有 TMO 的大户

C

Corient Private Wealth LP

+ 持有TMO

+50.10%

3个月收益率

W

W1M Investment Management Limited

+ 持有TMOGEV

+16.26%

3个月收益率

B

Braidwell LP

+ 持有TMO

+15.28%

3个月收益率

T

The Woodbridge Company Limited

+ 持有TMO

+13.82%

3个月收益率

H

Howard Capital Management, Inc.

+ 持有TMO

+12.71%

3个月收益率

R

RBC Europe Limited

+ 持有TMO

+11.89%

3个月收益率

事件时间线

2026-10-08 (ET)

14:30:00

Nvidia-Backed Lambda Raises $4B, Valuation at $14.5B

2026-10-06 (ET)

06:30:00

Quantum BioPharma Enters Study Start-Up Agreement with Thermo Fisher

2026-09-24 (ET)

06:30:00

Biodesix Advances Tumor-Informed and Tumor-Naive MRD Solutions

2026-09-23 (ET)

09:00:00

Thermo Fisher Launches Gibco CHO-K1 Product Portfolio

2026-09-22 (ET)

10:30:00

Trump Proposes $5B Investment in Middle East Energy Infrastructure

资讯

TMO 常见问题 —— 由 Alphio AI 解答

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies. It operates in the Healthcare sector (MEASURING & CONTROLLING DEVICES, NEC industry).

Thermo Fisher Scientific Inc is a good buy right now, with a current price of $690 and a forward P/E ratio of 24.15, indicating reasonable valuation compared to its growth prospects. The stock has shown a 5-day change of +4.86% and a year-to-date change of +16.45%, reflecting strong momentum. However, the RSI is at 68.22, suggesting it is nearing overbought territory, which is a risk to consider.

15 analysts cover TMO: 14 rate it Buy, 1 Hold and 0 Sell. The average price target is 658.89.

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易